Ultragenyx Pharmaceutical Inc.
Common Stock · USD · NASDAQ
Price
$22.76
Cap
—
Earnings
—
30d Trend
-7.3%
51% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 31×Macro 0.99 (−1%)=31
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 80%
BRAIN47 HORIZON ANALYSIS
Limited short-term thesis
BRAIN47'S ASSESSMENT
I rate Ultragenyx Pharmaceutical Inc. at 31/100 — a WEAK reading on the Brain47 Signal. The strongest factor is fundamentals at 50/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
-3.8%
3 MONTHS
-0.6%
12 MONTHS
-33.6%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Limited short-term thesis. Fundamentals (50) and Quality (49) are the primary strengths. I note that momentum is the weakest area at 13/100 — this warrants monitoring. Historical volatility is elevated at 51%. I classify this as a speculative position — elevated volatility at 51% and asymmetric payoff potential define the opportunity.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.